Curis to Present CUDC-101 Phase I Clinical Data and CU-201 Preclinical Data at the 22nd EORTC-NCI-AACR Symposium
- Poster presentations to highlight data and potential advantages of drug candidates from first-in-class series of compounds targeting HDAC, EGFR and Her2, and HDAC, Abl and Src family kinases -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 15, 2010 - Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that Curis scientists and collaborators will present data from two of its proprietary drug candidates at the 22nd EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics” held in Berlin, Germany, November 16-19, 2010.
- Rudi Bao, M.D., Ph.D., Curis' Senior Director of Oncology, will present a poster entitled, “Anti-Tumor Activity of CU-201, an Inhibitor of HDAC, SFK and Abl Kinases,” as part of the poster session on “Molecular-targeted therapies-preclinical” on November 17, 2010, at 12:00 pm CET.
- Toshio Shimizu, M.D., Ph. D., Visiting Clinical Fellow, South Texas Accelerated Research Therapeutics (START), will present a poster entitled, “The First-in-Human, First-in-Class Study of CUDC-101, a Multi-Targeted Inhibitor of HDAC, EGFR and HER2: A Phase I Study in Patients with Advanced Cancer,” as part of the poster session on "Molecular-targeted therapies-clinical trials," which is scheduled on November 18, 2010, at 12:00 pm CET.
Copies of the posters will be available on Curis' website, www.curis.com, following the presentations.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at www.curis.com.
Curis Cautionary Statement: This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements used in this press release may contain the words "believes", "expects", "anticipates", "plans", "seeks", "estimates”, “assumes”, "will", "may" or similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause the actual results to be materially different from those indicated by such forward-looking statements including, among other things Those risk factors identified in Curis' Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 and other filings that it periodically makes with the Securities and Exchange Commission.
In addition, any forward-looking statements represent the views only as of today and should not be relied upon as representing Curis' views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise.
Contact: Curis, Inc.
Michael P. Gray, 617-503-6632
Chief Financial and Chief Operating Officer
Posted: November 2010